Molecular Markers for Colorectal Cancer

被引：28
作者：
Wright, Moriah [1 ]
Beaty, Jenifer S. [2 ,3 ]
Ternent, Charles A. [2 ,3 ]
机构：
[1] Colon & Rectal Surg Inc, 9850 Nicholas St,Suite 100, Omaha, NE 68114 USA
[2] CHI Creighton Univ, Med Ctr Bergan Mercy, Dept Surg, 7500 Mercy Rd, Omaha, NE 68124 USA
[3] Univ Nebraska Med Ctr, Dept Surg, 5 42nd St & Emile St, Omaha, NE 68198 USA
来源：
SURGICAL CLINICS OF NORTH AMERICA | 2017年 / 97卷 / 03期
关键词：
Colorectal neoplasm; Drug therapy; Antineoplastic combined chemotherapy; Biomarkers; Tumor/genetics; Antibodies; Monoclonal/therapeutic use; III COLON-CANCER; THYMIDYLATE SYNTHASE INHIBITION; N-TERMINAL KINASE; CD8; T-CELLS; STAGE-II; 1ST-LINE TREATMENT; GENE-EXPRESSION; PHASE-III; MONOCLONAL-ANTIBODY; RANDOMIZED-TRIAL;
D O I：
10.1016/j.suc.2017.01.014
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Colorectal cancers develop through at least 3 major pathways, including chromosomal instability, mismatch repair, and methylator phenotype. These pathways can coexist in a single individual and occur in both sporadic and inherited colorectal cancers. In spite of the unique molecular and genetic signatures of colorectal cancers, nonspecific chemotherapy based on the antineoplastic effects of 5-fluorouracil is the cornerstone of therapy for stage III and some stage II disease. Techniques to recognize colorectal cancer at the molecular level have facilitated development of new signature drugs designed to inhibit the unique pathways of colorectal cancer growth and immunity.
引用
收藏
页码：683 / +
页数：20
相关论文
共 119 条
  • [21] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    Cunningham, D
    Pyrhönen, S
    James, RD
    Punt, CJA
    Hickish, TF
    Heikkila, R
    Johannesen, TB
    Starkhammar, H
    Topham, CA
    Awad, L
    Jacques, C
    Herait, P
    [J]. LANCET, 1998, 352 (9138) : 1413 - 1418
  • [22] Davies MM, 1999, CLIN CANCER RES, V5, P325
  • [23] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [24] Oxaliplatin, leucovorin and fluorouracil in pretreated patients with advanced colorectal cancer.
    deGramont, A
    Tournigand, C
    Louvet, C
    Andre, T
    Molitor, JL
    Raymond, E
    Moreau, S
    Vignoud, J
    LeBail, N
    Krulik, M
    [J]. REVUE DE MEDECINE INTERNE, 1997, 18 (10): : 769 - 775
  • [25] Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
  • [26] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
    Douillard, JY
    Cunningham, D
    Roth, AD
    Navarro, M
    James, RD
    Karasek, P
    Jandik, P
    Iveson, T
    Carmichael, J
    Alakl, M
    Gruia, G
    Awad, L
    Rougier, P
    [J]. LANCET, 2000, 355 (9209) : 1041 - 1047
  • [27] THE EFFECT OF DOSE AND INTERVAL BETWEEN 5-FLUOROURACIL AND LEUCOVORIN ON THE FORMATION OF THYMIDYLATE SYNTHASE TERNARY COMPLEX IN HUMAN CANCER-CELLS
    DRAKE, JC
    VOELLER, DM
    ALLEGRA, CJ
    JOHNSTON, PG
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (06) : 1145 - 1150
  • [28] UP-REGULATION OF CYCLOOXYGENASE-2 GENE-EXPRESSION IN HUMAN COLORECTAL ADENOMAS AND ADENOCARCINOMAS
    EBERHART, CE
    COFFEY, RJ
    RADHIKA, A
    GIARDIELLO, FM
    FERRENBACH, S
    DUBOIS, RN
    [J]. GASTROENTEROLOGY, 1994, 107 (04) : 1183 - 1188
  • [29] The MAPK signalling pathways and colorectal cancer
    Fang, JY
    Richardson, BC
    [J]. LANCET ONCOLOGY, 2005, 6 (05) : 322 - 327
  • [30] New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas
    Fanoni, D.
    Tavecchio, S.
    Recalcati, S.
    Balice, Y.
    Venegoni, L.
    Fiorani, R.
    Crosti, C.
    Berti, E.
    [J]. IMMUNOLOGY LETTERS, 2011, 134 (02) : 157 - 160
12345678910